1: Doudican NA, Mazumder A, Kapoor S, Sultana Z, Kumar A, Talawdekar A, Basu K, Agrawal A, Aggarwal A, Shetty K, Singh NK, Kumar C, Tyagi A, Singh NK, Darlybai JC, Abbasi T, Vali S. Predictive simulation approach for designing cancer therapeutic regimens with novel biological mechanisms. J Cancer. 2014 Apr 25;5(6):406-16. doi: 10.7150/jca.7680. eCollection 2014. PubMed PMID: 24847381; PubMed Central PMCID: PMC4026994. 2: De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546. doi: 10.1155/2013/291546. Epub 2013 Aug 29. Review. PubMed PMID: 24073332; PubMed Central PMCID: PMC3773450. 3: Metze K. Fractal dimension of chromatin: potential molecular diagnostic applications for cancer prognosis. Expert Rev Mol Diagn. 2013 Sep;13(7):719-35. doi: 10.1586/14737159.2013.828889. Review. PubMed PMID: 24063399; PubMed Central PMCID: PMC3821378. 4: Gourzones-Dmitriev C, Kassambara A, Sahota S, Rème T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B. DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle. 2013 Sep 1;12(17):2760-73. doi: 10.4161/cc.25951. Epub 2013 Aug 9. Review. PubMed PMID: 23966156; PubMed Central PMCID: PMC3899190. 5: Mullins CD, Su MY, Hucthagowder V, Chu L, Lu L, Kulkarni S, Novack D, Vij R, Tomasson MH. Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf. PLoS One. 2013 Jun 25;8(6):e67941. doi: 10.1371/journal.pone.0067941. Print 2013. PubMed PMID: 23825691; PubMed Central PMCID: PMC3692489. 6: Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014 Feb;28(2):384-90. doi: 10.1038/leu.2013.199. Epub 2013 Jul 2. PubMed PMID: 23817176; PubMed Central PMCID: PMC3916874. 7: Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11988-93. doi: 10.1073/pnas.1310230110. Epub 2013 Jun 26. Erratum in: Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):1760. PubMed PMID: 23803853; PubMed Central PMCID: PMC3718086. 8: Chang L, Guo R, Huang Q, Yen Y. Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms. Cell Rep. 2013 May 30;3(5):1389-97. doi: 10.1016/j.celrep.2013.03.040. Epub 2013 May 2. PubMed PMID: 23643536; PubMed Central PMCID: PMC3672259. 9: Righi M, Giacomini A, Cleris L, Carlo-Stella C. (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies. PLoS One. 2013;8(3):e59691. doi: 10.1371/journal.pone.0059691. Epub 2013 Mar 26. Erratum in: PLoS One. 2013;8(4). doi: 10.1371/annotation/f61040ca-4eab-4c4c-ad77-0a2ab8c503de. PubMed PMID: 23555747; PubMed Central PMCID: PMC3608557. 10: Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14;121(11):2051-8. doi: 10.1182/blood-2012-09-454355. Epub 2013 Jan 15. Erratum in: Blood. 2013 Jun 27;121(26):5259. Varettoni, Maria [corrected to Varettoni, Marzia]. PubMed PMID: 23321251; PubMed Central PMCID: PMC3596964. 11: Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M, Gordon LI, Rosen ST, Budunova I. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Cell Cycle. 2013 Jan 1;12(1):133-44. doi: 10.4161/cc.23048. Epub 2012 Dec 19. PubMed PMID: 23255118; PubMed Central PMCID: PMC3570502. 12: Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012 Oct 1;122(10):3456-63. doi: 10.1172/JCI61188. Epub 2012 Oct 1. Review. PubMed PMID: 23023717; PubMed Central PMCID: PMC3461901. 13: Vicente-Dueñas C, González-Herrero I, García Cenador MB, García Criado FJ, Sánchez-García I. Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB. Cell Cycle. 2012 Oct 15;11(20):3896-900. doi: 10.4161/cc.22186. Epub 2012 Sep 14. PubMed PMID: 22983007; PubMed Central PMCID: PMC3495831. 14: Sng J, Lufkin T. Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int. 2012;2012:521343. doi: 10.1155/2012/521343. Epub 2012 Aug 2. PubMed PMID: 22919402; PubMed Central PMCID: PMC3419439. 15: Shebl FM, Warren JL, Eggers PW, Engels EA. Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012 Jul 26;13:65. doi: 10.1186/1471-2369-13-65. PubMed PMID: 22834953; PubMed Central PMCID: PMC3441292. 16: Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest. 2012 Aug 1;122(8):2793-806. doi: 10.1172/JCI63051. Epub 2012 Jul 2. PubMed PMID: 22751105; PubMed Central PMCID: PMC3408744. 17: Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ 3rd, Lohr JG, Harris CC, Ding L, Wilson RK, Wheeler DA, Gibbs RA, Kucherlapati R, Lee C, Kharchenko PV, Park PJ; Cancer Genome Atlas Research Network. Landscape of somatic retrotransposition in human cancers. Science. 2012 Aug 24;337(6097):967-71. doi: 10.1126/science.1222077. Epub 2012 Jun 28. PubMed PMID: 22745252; PubMed Central PMCID: PMC3656569. 18: Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012 Aug 2;120(5):1060-6. doi: 10.1182/blood-2012-01-405977. Epub 2012 Apr 23. PubMed PMID: 22529291; PubMed Central PMCID: PMC3412329. 19: Fang HT, Zhang B, Pan XF, Gao L, Zhen T, Zhao HX, Ma L, Xie J, Liu Z, Yu XJ, Cheng X, Feng TT, Zhang FX, Yang Y, Hu ZG, Sheng GQ, Chen YL, Chen SJ, Chen Z, Zhou GB. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2521-6. doi: 10.1073/pnas.1121341109. Epub 2012 Jan 27. PubMed PMID: 22308476; PubMed Central PMCID: PMC3289299. 20: Jo SH, Ren R. IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner. J Biol Chem. 2012 Jan 13;287(3):1770-8. doi: 10.1074/jbc.M111.289728. Epub 2011 Nov 22. PubMed PMID: 22110133; PubMed Central PMCID: PMC3265859. 21: Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcia BA, Li W, Gozani O. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011 Nov 18;44(4):609-20. doi: 10.1016/j.molcel.2011.08.042. PubMed PMID: 22099308; PubMed Central PMCID: PMC3222870. 22: Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta. 2012 Jan;1825(1):64-76. doi: 10.1016/j.bbcan.2011.10.003. Epub 2011 Oct 18. Review. PubMed PMID: 22037302; PubMed Central PMCID: PMC3242858. 23: Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, Li GK, Jin DY, Chim CS. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One. 2011 Apr 22;6(4):e19027. doi: 10.1371/journal.pone.0019027. PubMed PMID: 21544199; PubMed Central PMCID: PMC3081325. 24: Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011 Jun;25(6):1026-35. doi: 10.1038/leu.2011.53. Epub 2011 Apr 5. PubMed PMID: 21468039; PubMed Central PMCID: PMC3432644. 25: Xu D, Meyer F, Ehlers E, Blasnitz L, Zhang L. Interferon regulatory factor 4 (IRF-4) targets IRF-5 to regulate Epstein-Barr virus transformation. J Biol Chem. 2011 May 20;286(20):18261-7. doi: 10.1074/jbc.M110.210542. Epub 2011 Mar 24. PubMed PMID: 21454650; PubMed Central PMCID: PMC3093898. 26: Mi L, Gan N, Chung FL. Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells. Carcinogenesis. 2011 Feb;32(2):216-23. doi: 10.1093/carcin/bgq242. Epub 2010 Nov 25. PubMed PMID: 21109604; PubMed Central PMCID: PMC3026846. 27: Keefer LK; behalf of the JS-K Consortium. Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates. For Immunopathol Dis Therap. 2010 Jul 1;1(3):205-218. PubMed PMID: 21949595; PubMed Central PMCID: PMC3179376. 28: de Jong D, Janz S. Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia. J Pathol. 2010 Jul;221(3):242-7. doi: 10.1002/path.2714. PubMed PMID: 20527018; PubMed Central PMCID: PMC3118561. 29: Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S, Aggarwal BB. Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 2010 May;8(5):751-61. doi: 10.1158/1541-7786.MCR-09-0565. Epub 2010 May 11. PubMed PMID: 20460401; PubMed Central PMCID: PMC2895997. 30: Sandur SK, Pandey MK, Sung B, Aggarwal BB. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res. 2010 Jan;8(1):107-18. doi: 10.1158/1541-7786.MCR-09-0257. Epub 2010 Jan 12. PubMed PMID: 20068065; PubMed Central PMCID: PMC2808447. 31: Haridas V, Nishimura G, Xu ZX, Connolly F, Hanausek M, Walaszek Z, Zoltaszek R, Gutterman JU. Avicin D: a protein reactive plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and phosphatase activities. PLoS One. 2009;4(5):e5578. doi: 10.1371/journal.pone.0005578. Epub 2009 May 18. PubMed PMID: 19440292; PubMed Central PMCID: PMC2680980. 32: Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem. 2009 May 8;284(19):12886-95. doi: 10.1074/jbc.M806546200. Epub 2009 Mar 11. PubMed PMID: 19279006; PubMed Central PMCID: PMC2676019. 33: Zapata JM, Llobet D, Krajewska M, Lefebvre S, Kress CL, Reed JC. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood. 2009 May 7;113(19):4595-603. doi: 10.1182/blood-2008-07-165456. Epub 2008 Dec 12. PubMed PMID: 19074733; PubMed Central PMCID: PMC2680366. 34: Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica. 2009 Jan;94(1):87-93. doi: 10.3324/haematol.13483. Epub 2008 Nov 10. PubMed PMID: 19001278; PubMed Central PMCID: PMC2625405. 35: Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang XY, Zimonjic DB, Popescu NC. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia. 2009 Feb;23(2):383-90. doi: 10.1038/leu.2008.285. Epub 2008 Oct 16. PubMed PMID: 18923442; PubMed Central PMCID: PMC2790147. 36: Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM. IRF4 addiction in multiple myeloma. Nature. 2008 Jul 10;454(7201):226-31. doi: 10.1038/nature07064. Epub 2008 Jun 22. PubMed PMID: 18568025; PubMed Central PMCID: PMC2542904. 37: Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008 Dec;22(12):2280-4. doi: 10.1038/leu.2008.142. Epub 2008 Jun 5. PubMed PMID: 18528420; PubMed Central PMCID: PMC3864109. 38: Yu X, McGraw PA, House FS, Crowe JE Jr. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. J Immunol Methods. 2008 Jul 31;336(2):142-51. doi: 10.1016/j.jim.2008.04.008. Epub 2008 May 5. PubMed PMID: 18514220; PubMed Central PMCID: PMC2519117. 39: Kinyamu HK, Collins JB, Grissom SF, Hebbar PB, Archer TK. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition. Mol Carcinog. 2008 Nov;47(11):845-85. doi: 10.1002/mc.20440. PubMed PMID: 18381591; PubMed Central PMCID: PMC2863309. 40: Kim JY, Kee HJ, Choe NW, Kim SM, Eom GH, Baek HJ, Kook H, Kook H, Seo SB. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol. 2008 Mar;28(6):2023-34. doi: 10.1128/MCB.02130-07. Epub 2008 Jan 2. PubMed PMID: 18172012; PubMed Central PMCID: PMC2268398. 41: Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007 Sep;12(3):201-14. PubMed PMID: 17785202; PubMed Central PMCID: PMC2424114. 42: Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics. 2007 Aug 31;8:302. PubMed PMID: 17764563; PubMed Central PMCID: PMC2040348. 43: Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol. 2007 Sep;81(18):10029-36. Epub 2007 Jul 11. PubMed PMID: 17626072; PubMed Central PMCID: PMC2045383. 44: Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, Xie Y. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol. 2006 Sep;59(9):947-51. Epub 2006 Feb 17. PubMed PMID: 16489177; PubMed Central PMCID: PMC1860476. 45: Chen J, Williams IR, Lee BH, Duclos N, Huntly BJ, Donoghue DJ, Gilliland DG. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood. 2005 Jul 1;106(1):328-37. Epub 2005 Mar 22. PubMed PMID: 15784730; PubMed Central PMCID: PMC1895117. 46: To KF, Chan MW, Leung WK, Ng EK, Yu J, Bai AH, Lo AW, Chu SH, Tong JH, Lo KW, Sung JJ, Chan FK. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer. 2004 Oct 4;91(7):1335-41. PubMed PMID: 15354212; PubMed Central PMCID: PMC2409891. 47: Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, Van Kessel B, Van Blokland WT, Bloem AC, Lokhorst HM. Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma. Clin Exp Immunol. 2003 Feb;131(2):340-6. PubMed PMID: 12562398; PubMed Central PMCID: PMC1808635. 48: Pratt G. Molecular aspects of multiple myeloma. Mol Pathol. 2002 Oct;55(5):273-83. Review. PubMed PMID: 12354927; PubMed Central PMCID: PMC1187254. 49: O'Leary JJ, Silva I, Uhlmann V, Prasad M, Luttich K, Maffei A, Picton S. Hypothesis. HHV-8 in multiple myeloma: is this the first paracrine model of human tumorigenesis and do Koch's postulates apply? Mol Pathol. 1998 Aug;51(4):201-3. PubMed PMID: 9893745; PubMed Central PMCID: PMC395636. 50: Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998 Jan 1;91(1):3-21. Review. PubMed PMID: 9414264; PubMed Central PMCID: PMC3901996. 51: Pattengale PK. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma. Am J Pathol. 1997 Sep;151(3):647-9. PubMed PMID: 9284811; PubMed Central PMCID: PMC1857849. 52: Olujohungbe A, Handa S, Holmes J. Does erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J. 1997 Mar;73(857):163-4. PubMed PMID: 9135833; PubMed Central PMCID: PMC2431253. 53: Hilbert DM, Kopf M, Mock BA, Köhler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995 Jul 1;182(1):243-8. PubMed PMID: 7790819; PubMed Central PMCID: PMC2192088. 54: Hilbert DM, Shen MY, Rapp UR, Rudikoff S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):649-53. PubMed PMID: 7846031; PubMed Central PMCID: PMC42677. 55: MacKenzie T, Dosch HM. Clonal and molecular characteristics of the human IgE-committed B cell subset. J Exp Med. 1989 Feb 1;169(2):407-30. PubMed PMID: 2536066; PubMed Central PMCID: PMC2189205. 56: Wasylyk C, Imler JL, Wasylyk B. Transforming but not immortalizing oncogenes activate the transcription factor PEA1. EMBO J. 1988 Aug;7(8):2475-83. PubMed PMID: 3142763; PubMed Central PMCID: PMC457117. 57: Croese JW, Vas Nunes CM, Radl J, van den Enden-Vieveen MH, Brondijk RJ, Boersma WJ. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer. 1987 Nov;56(5):555-60. PubMed PMID: 3426918; PubMed Central PMCID: PMC2001900. 58: Nathan PD, Walker L, Hardie D, Richardson P, Khan M, Johnson GD, Ling NR. An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigen. Clin Exp Immunol. 1986 Jul;65(1):112-9. PubMed PMID: 3024883; PubMed Central PMCID: PMC1542266. 59: Thompson KM, Melamed MD, Eagle K, Gorick BD, Gibson T, Holburn AM, Hughes-Jones NC. Production of human monoclonal IgG and IgM antibodies with anti-D (rhesus) specificity using heterohybridomas. Immunology. 1986 May;58(1):157-60. PubMed PMID: 3011653; PubMed Central PMCID: PMC1452628. 60: Drexler HG, Klein M, Bhoopalam N, Gaedicke G, Minowada J. Morphological and isoenzymatic differentiation of B-chronic lymphocytic leukaemia cells induced by phorbolester. Br J Cancer. 1986 Feb;53(2):181-8. PubMed PMID: 3485441; PubMed Central PMCID: PMC2001325. 61: Hulette CM, Effros RB, Dillard LC, Walford RL. Production of a human monoclonal antibody to HLA by human-human hybridoma technology. A preliminary report. Am J Pathol. 1985 Oct;121(1):10-4. PubMed PMID: 2996358; PubMed Central PMCID: PMC1888038. 62: Pilarski LM, Ruether BA, Mant MJ. Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels. J Clin Invest. 1985 Jun;75(6):2024-9. PubMed PMID: 2989339; PubMed Central PMCID: PMC425563. 63: Sutherland BM, Bennett PV, Freeman AG, Moore SP, Strickland PT. Transformation of human cells by DNAs ineffective in transformation of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2399-403. PubMed PMID: 3857589; PubMed Central PMCID: PMC397565. 64: McGowan JJ, Wagner RR. Inhibition of cellular DNA synthesis by vesicular stomatitis virus. J Virol. 1981 Apr;38(1):356-67. PubMed PMID: 6165831; PubMed Central PMCID: PMC171158. 65: Vanhegan RI. Distribution of malignant lymphoid cells. J Clin Pathol Suppl (R Coll Pathol). 1979;13:70-5. Review. PubMed PMID: 391828; PubMed Central PMCID: PMC1521583. 66: Aoki T, Todaro GJ. Antigenic properties of endogenous type-C viruses from spontaneously transformed clones of BALB-3T3. Proc Natl Acad Sci U S A. 1973 May;70(5):1598-602. PubMed PMID: 4351184; PubMed Central PMCID: PMC433550.